Bluesky Facebook Reddit Email

Early adoption of anti–SARS-CoV-2 pharmacotherapies among veterans with mild to moderate COVID-19

11.11.22 | JAMA Network

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

About The Study: In this study of more than 111,000 veterans who tested positive for SARS-CoV-2 during January and February 2022 when supply of outpatient COVID-19 pharmacotherapies was limited, prescription of these pharmacotherapies was underused, and many veterans with risk factors for severe COVID-19 did not receive treatment. Veterans from minority racial and ethnic groups were less likely to receive any pharmacotherapy.

Authors: Kristina L. Bajema, M.D., M.Sc., of the Veterans Affairs Portland Health Care System in Portland, Oregon, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.41434)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.41434?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111122

About JAMA Network Open : JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

JAMA Network Open

Keywords

Article Information

Contact Information

JAMA Network Media Relations
JAMA Network
mediarelations@jamanetwork.org

How to Cite This Article

APA:
JAMA Network. (2022, November 11). Early adoption of anti–SARS-CoV-2 pharmacotherapies among veterans with mild to moderate COVID-19. Brightsurf News. https://www.brightsurf.com/news/LN27WRE1/early-adoption-of-antisars-cov-2-pharmacotherapies-among-veterans-with-mild-to-moderate-covid-19.html
MLA:
"Early adoption of anti–SARS-CoV-2 pharmacotherapies among veterans with mild to moderate COVID-19." Brightsurf News, Nov. 11 2022, https://www.brightsurf.com/news/LN27WRE1/early-adoption-of-antisars-cov-2-pharmacotherapies-among-veterans-with-mild-to-moderate-covid-19.html.